Abstract:The rising global prevalence of metabolic diseases has increased the prevalence of non-alcoholic fatty liver disease (NAFLD), leading to an increase in cases of NAFLD-related hepatocellular carcinoma (HCC). To provide an updated literature review detailing epidemiology, risk factors, pathogenic pathways, and treatment strategies linked to NAFLD-related HCC, we conducted a literature search on PubMed from its inception to December 31, 2021. About 25% of the global population suffers from NAFLD. The annual incidence of HCC among NAFLD patients is approximately 1.8 per 1,000 person-years. Older age, male sex, metabolic comorbidities, unhealthy lifestyle habits (such as smoking and alcohol consumption), physical inactivity, genetic susceptibility, liver fibrosis, and degree of cirrhosis in NAFLD patients are important risk factors for NAFLD-related HCC. Therefore, low-calorie diet, moderate-intensity exercise, treatment of metabolic comorbidities, and cessation of smoking and alcohol are the main measures to prevent NAFLD-related HCC. In addition, all patients with advanced NAFLD-related fibrosis or cirrhosis should be screened for HCC. Immune suppression disorders and changes in the liver microenvironment may be the main pathogenesis of NAFLD-related HCC. Hepatic resection, liver transplantation, ablation, transarterial chemoembolization, radiotherapy, targeted drugs, and immune checkpoint inhibitors are used to treat NAFLD-related HCC. Lenvatinib treatment may lead to better overall survival, while immune checkpoint inhibitors may lead to worse overall survival. Given the specific risk factors for NAFLD-related HCC, primary prevention is key. Moreover, the same treatment may differ substantially in efficacy against NAFLD-related HCC than against HCC of other etiologies.

Prevalence of benign focal liver lesions and non-hepatocellular carcinoma malignant lesions in liver cirrhosis

Focal Benign Liver Lesions and Their Diagnostic Pitfalls

Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link

Focal nodular hyperplasia-like lesions in patients with cavernous transformation of the portal vein: prevalence, MR findings and natural history

Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease

Clinical analysis of fibrolamellar hepatocellular carcinoma,two cases report and a review of the literature

[Focal Nodular Hyperplasia of Liver: a Clinicopathologic Study of 238 Patients].

Prevalence of Chronic Liver Disease in Cholangiocarcinoma: A Meta-Analysis

Advances in the Study of Non-Infectious Liver Diseases and Precancerous Lesions of Hepatocellular Carcinoma

Focal Nodular Hyperplasia of the Liver in 86 Patients.

Benign pericholecystic regeneration mimicking hepatocellular carcinoma: a potential pitfall in imaging of cirrhosis

ACG Clinical Guideline: Focal Liver Lesions

Non-Parenchymal Cells and the Extracellular Matrix in Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease

Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges

WFUMB Review Paper. Incidental Findings in Otherwise Healthy Subjects, How to Manage: Liver

Benign liver tumours: understanding molecular physiology to adapt clinical management

[An Analysis of Clinical Characteristics and Risk Factors of Cirrhosis-Related Hepatocellular Carcinomas in Patients with Hepatitis C Virus Infection].

Accumulation of Genetic and Epigenetic Alterations in the Background Liver and Emergence of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease

Fungal infections in liver cirrhosis

Diagnosis and Assessment of Liver Cirrhosis

Ultrasound-guided percutaneous biopsy for focal liver lesions: Adverse events and diagnostic yield in a single-centre analysis